An Insoluble Problem?

The challenges of crystallizing membrane proteins—and how they’re being overcome.

Written byRobert Michael Stroud
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Computer artwork of a G protein-coupled receptor in the lipid bilayer of a plasma membraneMEDI-MATION LTD / PHOTO RESEARCHERSMembrane proteins represent only a handful of the total number of protein structures defined to date. Yet these proteins, which represent nearly 40 percent of all known proteins, including receptors, channels, and signaling molecules, are essential for cell communication and their malfunctions are implicated in many diseases. Structure-based design is one powerful way of developing drugs tuned to the precise actions and minimal side effects required for effective treatments. X-ray crystallography—still the only general method for solving the atomic structures of proteins of any size—has been hampered by the extreme difficulty of preparing and crystallizing pure membrane proteins.

The problem is a practical one: hydrophilic proteins, such as those in the cytoplasm, can form crystals in solution relatively easily, but membrane proteins also have hydrophobic parts that buoy the protein in the lipid layer. To maintain their shape, these lipid-loving domains must be surrounded by components that resemble the natural membrane—a requirement that makes it difficult to grow well-diffracting crystals. However, an array of technical advances over the last 2 years has advanced our ability to determine these structures.

Advances are the result of developments at multiple steps in the crystallization process. One example comes from Raymond Stevens and colleagues at the Scripps Research Institute who discovered that lipids were essential for determining the structure of a G protein-coupled receptor (GPCR) that responds ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies